Evidence map›Paper›PMID 36135743›Full record

ArticleMarine drugs2022

Targeted Isolation of Antibiotic Brominated Alkaloids from the Marine Sponge

James Lever, Florian Kreuder, Jason Henry, Andrew Hung, Pierre-Marie Allard, Robert Brkljača, Colin Rix, Aya C Taki, Robin B Gasser, Jan Kaslin and 3 more

Abstract read
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

James LeverSchool of Science (Applied Chemistry and Environmental Sciences), RMIT University, GPO Box 2476 Melbourne, VIC 3001, Australia.
Florian KreuderAustralian Regenerative Medicine Institute, Monash University, Clayton, VIC 3800, Australia.
Jason HenryNeurotoxicology Lab., School of Science (Biosciences), RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0002-0059-3868
Andrew HungSchool of Science (Applied Chemistry and Environmental Sciences), RMIT University, GPO Box 2476 Melbourne, VIC 3001, Australia.ORCID 0000-0003-3569-2951
Pierre-Marie AllardDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0003-3389-2191
Robert BrkljačaMonash Biomedical Imaging, Monash University, Clayton, VIC 3168, Australia.
Colin RixSchool of Science (Applied Chemistry and Environmental Sciences), RMIT University, GPO Box 2476 Melbourne, VIC 3001, Australia.
Aya C TakiDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary and Agriculture Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.ORCID 0000-0003-3489-4367
Robin B GasserDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary and Agriculture Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.ORCID 0000-0002-4423-1690
Jan KaslinAustralian Regenerative Medicine Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-6207-1889
Donald WlodkowicNeurotoxicology Lab., School of Science (Biosciences), RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0002-0780-3362
Jean-Luc WolfenderSchool of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0002-0125-952X
Sylvia UrbanSchool of Science (Applied Chemistry and Environmental Sciences), RMIT University, GPO Box 2476 Melbourne, VIC 3001, Australia.ORCID 0000-0002-2376-4260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many targeted natural product isolation approaches rely on the use of pre-existing bioactivity information to inform the strategy used for the isolation of new bioactive compounds. Bioactivity information can be available either in the form of prior assay data or via Structure Activity Relationship (SAR) information which can indicate a potential chemotype that exhibits a desired bioactivity. The work described herein utilizes a unique method of targeted isolation using structure-based virtual screening to identify potential antibacterial compounds active against MRSA within the marine sponge order Verongiida. This is coupled with molecular networking-guided, targeted isolation to provide a novel drug discovery procedure. A total of 12 previously reported bromotyrosine-derived alkaloids were isolated from the marine sponge species Pseudoceratina durissima, and the compound, (+)-aeroplysinin-1 (1) displayed activity against the MRSA pathogen (MIC: <32 µg/mL). The compounds (1−3, 6 and 9) were assessed for their central nervous system (CNS) interaction and behavioral toxicity to zebrafish (Danio rerio) larvae, whereby several of the compounds were shown to induce significant hyperactivity. Anthelmintic activity against the parasitic nematode Haemonchus contorutus was also evaluated (2−4, 6−8).

Indexed as

AlkaloidsAnthelminticsBiological ProductsPoriferaAnimalsAnti-Bacterial AgentsMolecular StructureZebrafishAlkaloidsAnthelminticsAnti-Bacterial AgentsBiological Productschemical space topologycheminformatic analysisin silico molecular dockingmolecular networkingMRSA pathogensponge metabolitestargeted anti-biotic isolationvirtual screeningzebrafish

Identifiers

PMID36135743
PMCPMC9503778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.